SecBot SecBot
S-4/A425 ·Filed Sep 2, 2026

PASG

Passage BIO, Inc.
BEARISH
Impact 8/10
Horizonmonths Processed2mo ago SEC0001140361-26-035517
Actionable Insight ▼ Bearish

The transaction is an effective acquisition of Passage Bio by Remix, with Passage Bio shareholders receiving minimal ongoing stake (6%) and only speculative, potentially valueless CVRs. The concurrent $100M financing is contingent on closing, and the combined company has a highly risky, early-stage pipeline with one clinical candidate. With current PASG holders facing near-total ownership extinction and no path to independent revenue, the stock is likely to trade toward the implied economics of the deal. Traders should monitor the special meeting vote and any hold-out investors; post-merger, the combined entity (RMTX) remains a high-risk clinical-stage biotech.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$4.75
T+0 close · Sep 2, 2026 · via day close
Latest settled
−13.26%
T+20 · $4.12 · next T+60 in 13d
Vs SPY
−12.08%
α at T+20
Latest observation
+8.06%
T+50 · FF3 residual α
  1. T+0 · Sep 3 $4.75entry
  2. T+1 · 2mo ago −2.11%α −1.72% · $4.65
  3. T+5 · 2mo ago +5.26%α +6.41% · $5.00
  4. T+20 · 7w ago −13.26%α −12.08% · $4.12
  5. T+51 · todayOpen
  6. T+60 · in 13d Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Passage Bio filed an amended S-4 (S-4/A) detailing its proposed reverse merger with Remix Therapeutics, where Remix will become a wholly owned subsidiary and Passage Bio will change its name to Remix Therapeutics, Inc. Pre-merger Passage Bio equity holders are expected to own approximately 6% of the combined company, while Remix equity holders and concurrent financing investors are expected to own approximately 65% and 29%, respectively. The concurrent financing, via a Subscription Agreement and convertible notes, is expected to raise approximately $100 million in gross proceeds, with the closing conditioned on the merger, and Passage Bio's remaining assets from its GM1 and MLD programs are being packaged into contingent value rights (CVRs) for current Passage Bio stockholders that may expire worthless.

Key Facts

  • Pre-merger Passage Bio equity holders will own approximately 6% of the combined company; Remix equity holders ~65%, concurrent financing investors ~29%.
  • Concurrent financing expected to raise ~$100.0 million, but is conditioned on merger closing.
  • Passage Bio equity holders will receive one CVR per share for proceeds from Gemma Biotherapeutics license arrangements (GM1 and MLD), which may expire worthless.
  • Passage Bio's net cash at closing is anticipated to be approximately $10.9 million, but its valuation for the exchange ratio is based on an assumed $5.0 million net cash; Passage Bio's net cash is nearly fully depleted beyond immediate obligations.
  • Passage Bio has wound down development programs, reduced workforce by ~75%, and has incurred net losses of $15.4 million and $24.8 million in the six months ended June 30, 2026 and 2025, respectively.
  • Passage Bio has an accumulated deficit of $720.1 million as of June 30, 2026.
  • Passage Bio currently only has ~$46.3 million in cash as of Dec 31, 2025, and has no path to revenue.
  • Merger agreement includes a termination fee of $1.5 million payable by Passage Bio under certain circumstances.
  • Remix has only one clinical-stage asset, REM-422, in Phase 1/2 for AML/HR-MDS/ACC, is a pre-revenue clinical-stage biotech, and has a going concern uncertainty.
  • Lock-up agreements restrict sales of combined company stock for 180 days post-closing for ~99% of Remix capital stock holders.

Financial Impact

Passage Bio stockholders diluted to ~6% ownership; net cash at closing anticipated ~$10.9 million; combined company expected to have ~$100M gross proceeds from concurrent financing but equity value of Remix only $226M vs zero revenue; CVRs for GM1/MLD may yield nothing.

ownership_dilutionnet_cashtotal_value

Risk Factors

  • Transaction may not close; if terminated, Passage Bio may liquidate with minimal or zero distribution to shareholders.
  • CVRs tied to Gemma sublicenses may never pay out (GM1 payment deadline July 31, 2028; MLD deadline Dec 31, 2027).
  • Remix has going concern uncertainty in its own standalone financials.
  • Combined company will face significant integration challenges and cash burn as a clinical-stage entity.
  • If Concurrent Financing does not close, combined company will have insufficient capital.
  • Post-merger stock (RMTX) is subject to lock-up expiration 180 days after close, adding selling pressure.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
67% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 2 SEC documents filed with EDGAR.

DocumentAccession Number
S-4/A Filing (PASG), Batch item 10001140361-26-035517
Document: ny20077915x3_ex10-36.htm0001140361-26-035516

Track record

15 reports on PASG

Performance horizon

1 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +22.24% at T+60 after the May 27, 2026 report. 3 of 6 went positive at some point.

Filters
  1. Nov 6, 202610d ago 8-K Neutral 5/10 Entry $3.98 Now $4.13 +3.90% settles Dec 7
  2. Oct 13, 20265w ago EFFECT Neutral 3/10 Entry $3.64 to $3.78 Now $4.13 +13.46% ▲ +3.85% +7.46% vs SPY
  3. Oct 8, 20265w ago S-4/A Bearish 6/10 Entry $3.69 to $3.98 Now $4.13 −11.92% ▼ −7.72% −13.28% vs SPY
  4. Oct 5, 20266w ago S-4/A Neutral 5/10 Entry $4.08 to $3.41 Now $4.13 +1.23% ▼ −16.47% −13.56% vs SPY
  5. Sep 21, 20268w ago S-4/A Neutral 5/10 Entry $4.95 to $3.60 Now $4.13 −16.57% ▼ −27.27% −26.71% vs SPY
  6. Sep 2, 202610w ago S-4/A / 425 Bearish 8/10 Viewing Entry $4.75 to $4.12 Now $4.13 +13.05% ▲ +13.26% +12.08% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 8/10 Entry $4.75 to $4.12 Now $4.13 −13.05% ▼ −13.26% −12.08% vs SPY
  8. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  9. Jun 24, 202620w ago 425 Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
  10. Jun 24, 202620w ago 8-K Bearish 7/10 Entry $4.33 to $4.90 Now $4.13 +4.62% ▼ −13.16% −12.64% vs SPY
Showing 10 of 15

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Sep 3, 2026